18 April 2024: Articles
Transformation of Severe Aplastic Anemia into Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Rare Case Report
Rare disease
Qianqian Wang * , Hong Xu * , Wei Yu B , Lingjie Sun B , Hongguo Zhao B , Xue Shi A*DOI: 10.12659/AJCR.943801
Am J Case Rep 2024; 25:e943801
Table 1. The brief comparison of the similarities and differences between our case and the other 5 cases.
| Basic characteristics of patients/references | Transplantation types | Donor types | Time of DCL occurrence after transplantation | DCL subtypes | Cytogenetic and Molecular Features | Treatments | Outcomes |
|---|---|---|---|---|---|---|---|
| 19-year-old male/Browne et al, 1991 []4 | Allo-BMT | MSD | 9 months | AML-M5a | / | Chemotherapy | CR |
| 12-year-old female/Lawler et al, 2001 []5 | Two times allo-BMT | MSD | 208 days | AML- M0 | / | Chemotherapy | Died of leukemia progression (+310 day) |
| 23-year-old male/Otero et al, 2012 []6 | Allo-BMT | MSD | 2 years | AML-M4/M5 | Monosomy 7 | A second allo-PBSCT from the same donor | Died of refractory septic shock (+15 day) |
| 15-year-old male/Manivannan et al, 2014 []7 | Allo-PBSCT | MSD | 660 days | AML-M4 | Complex karyotype [46,XY (80%)/45,XY,del(7q),−20 (10%)/hyperdiploidy (10%)] | Chemotherapy and followed by a second allo-PBSCT from another donor | CR (+180 day) |
| 25-year-old male/Ma and Liu, 2016 []8 | Allo-PBSCT | MSD | 2.5 years | AML-M2 | t(8;21) (q22;q22);+8; AML1-ETO | Chemotherapy and maintenance therapy with interleukin-2 | Molecular remission for>3 years |
| 51-year-old female/Present paper | Allo-PBSCT | MSD | 445 days | AML-M5 | Chemotherapy | Died of leukemia progression (+575 day) | |
| DCL – donor cell leukemia; allo-BMT – allogeneic bone marrow transplantation; MSD – matched sibling donor; AML – acute myeloid leukemia; CR – complete remission; allo-PBSCT – allogeneic peripheral blood stem cell transplantation. | |||||||